Comparing Impact of Panel Composition on Tumor Mutational Burden Calculation
November 15th 2019Nicholas Bevins, MD, PhD, discusses the results from an in silico comparison of frequently used next-generation sequencing panels. The analysis aimed to identify the impact of the panel composition on tumor mutational burden calculations. Results from the analysis were presented in a poster at the 2019 Association for Molecular Pathology Annual Meeting and Expo.
Watch
DNA-Based NGS Panel Accurately Detects MET Exon 14 Skipping Mutations in NSCLC
November 14th 2019In an interview with Targeted Oncology, Willemina R. Geurts-Giele, PhD, discussed the accuracy of detecting MET exon 14 skipping mutations in patients with NSCLC with DNA-based NGS panels. These findings were presented at The Association for Molecular Pathology Annual Meeting and Expo.
Read More
Resistance Mutations Pose Complex Challenges for Pathologists
November 13th 2019The emergence of resistance mutations in patients with cancer who receive targeted therapies is an expected development that will require new diagnostic methods of identifying the mechanisms through which these alterations occur, according to Fei Dong, MD, during the 2019 Association for Molecular Pathology Annual Meeting.<br />
Read More
Plasma Genotyping May Change Practice in NSCLC, Says Li
November 12th 2019In a presentation describing the utility of circulating tumor DNA liquid biopsy assays at the 14th Annual New York Lung Cancers Symposium, Bob T. Li, MD, MPH, said that plasma genotyping demsonstrates practice-changing potential in non–small cell lung cancer.
Read More
Genetic Testing is Essential in NSCLC Prior to Induction Therapy
November 12th 2019Testing for driver mutations is essential before initiating therapy in patients with non–small cell lung cancer, because there is a risk that the type of upfront treatment chosen could add to the toxicity of, and spur resistance to, targeted therapy options, Suresh S. Ramalingam, MD, said at the 14th Annual New York Lung Cancers Symposium.
Read More
Osimertinib Established as Preferred EGFR TKI Treatment in EGFR-Mutated NSCLC
November 12th 2019In an interview with Targeted Oncology during the 14th Annual New York Lung Cancers Symposium, Zofia Piotrowska, MD, MHS, discussed the role of osimertinib in treating patients with EGFR-mutant NSCLC and how it compares with other therapeutic options in that space.
Read More
Study Depicts Complexity of MET Exon 14 Mutation Testing
November 11th 2019The identification of <em>MET </em>exon 14 skipping mutations in patients with non–small cell lung cancer presents a complex diagnostic challenge that requires both DNA and RNA analysis, according to results of a University of Michigan pathology study.
Read More
Neoadjuvant Immunotherapy Holds Promise for Patients With Resectable NSCLC
November 10th 2019According to Tina Cascone, MD, PhD, in a presentation during the 14th Annual New York Lung Cancers Symposium, neoadjuvant immunotherapy is under investigation for patients with non–small cell lung cancer and holds hope as a treatment for patients.
Read More
Expert Reviews Evolving Treatment Options for Nondriver and Molecularly Driven NSCLC
November 10th 2019In an interview with <em>Targeted Oncology</em> during the <em>14th Annual </em>New York Lung Cancers Symposium, Benjamin P. Levy, MD, discussed therapeutic strategies for patients with oncogenic-driven and nondriver NSCLC.
Read More
Expert Discusses Benefits of Preoperative Therapy for NSCLC
November 10th 2019Noeadjuvant therapy for lung cancer provides significant benefits compared with adjuvant therapy, according to Jamie E. Chaft, MD. In a presentation at the <em>14th Annual </em>New York Lung Cancers Symposium, Chaft explained why neoadjuvant therapy is beneficial even though adjuvant therapy is still the standard of care at a number of cancer centers.
Read More
Expert Highlights the Clinical Utility of RNA Sequencing Methods in Cancer
November 9th 2019Kevin Halling, MD, PhD, discussed the clinical utility of RNA-sequencing methods in patients with cancer at the 2019 Association for Molecular Pathology Annual Meeting and Expo. Halling says RNA sequencing is a very powerful diagnostic technique.
Watch
Fisch Highlights Patient Case of Relapse Following Gilteritinib Treatment in FLT3-TKD+ AML
November 8th 2019At the 2019 Association for Molecular Pathology Annual Meeting and Expo, Adam Fisch, MD, PhD, presented a unique patient case where a patient with acute myeloid leukemia harboring a <em>FLT3</em>-TKD mutation lost the mutation following relapse on gilteritinib.<br />
Read More
Dynamic Tumor Cell Profiling Technique Correlates With Therapy Responses
November 8th 2019A technique involving BH3 profiling is emerging as a promising drug discovery tool for assessing whether a tumor is primed for cell death and would respond to anticancer therapy, according to a presentation at the 2019 Association for Molecular Pathology Annual Meeting.
Read More
More Frontline PARP Indications Are Expected in Ovarian Cancer
November 8th 2019PARP inhibitors are increasingly relevant for frontline maintenance indications and potentially in combination with chemotherapy for treatment-naïve ovarian cancer, including for those with <em>BRCA</em>-wildtype disease, Leslie M. Randall, MD, said to the audience at the <em>37th Annual</em> CFS.
Read More
Wealth of Options Available for Adjuvant Melanoma Therapy
November 8th 2019Immunotherapies and targeted therapies have greatly impacted the treatment of advanced melanoma and are beginning to make their way into earlier settings, with FDA approvals for adjuvant therapies and studies ongoing in the neoadjuvant space, according to a presentation by Jeffrey S. Weber, MD, PhD, at the <em>37th Annual</em> CFS.
Read More
BCMA-Directed Therapies Taking Hold in Multiple Myeloma
November 7th 2019There are at least two dozen different B-cell maturation antigen-directed therapies being explored in clinical trials, Sham Mailankody, MBBS, told attendees at the 37 Annual CFS. Mailankody, an assistant attending physician at Memorial Sloan Kettering Cancer Center in New York, New York, highlighted the most promising anti-BCMA agents across several modalities, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates.
Read More
Weighing Treatment Options in Newly Diagnosed Follicular Lymphoma
November 7th 2019Deciding between a watch-and-wait approach and systemic therapy in patients with newly diagnosed follicular lymphoma should be carefully assessed based on specific disease characteristics, with follow-up tailored toward patients’ risk of relapse, according to John P. Leonard, MD.
Read More
Novel Combinations Represent Next Phase for Adult ALL
November 7th 2019A number of promising biologic therapies are beginning to transform the treatment of adult patients with acute lymphoblastic leukemia, with the greatest potential seen with blinatumomab and inotuzumab ozogamicin in combination with chemotherapy, according to a presentation by Hagop M. Kantarjian, MD, at the 37th Annual CFS.<br />
Read More
Targeted Agents May Be Moving Closer to Frontline for Treatment of mCRC
October 14th 2019Treatment targeting molecular pathways such as <em>BRAF, </em>HER2<em>,</em> and <em>RAS</em> has typically been reserved for later lines of therapy for patients with metastatic colorectal cancer. Benjamin A. Weinberg, MD, said that agents targeting these pathways are not yet ready for the upfront setting, but data from ongoing trials suggest that these agents may eventually have a role to play in first- and second-line treatment.
Read More
Expert Compares Data for Immunotherapy Versus Chemotherapy In GEJ Cancer
October 14th 2019In an interview with <em>Targeted Oncology</em>, Daniel Catenacci, MD, discussed the clinical trials supporting immunotherapeutic options for patients with GEJ cancer. He also highlighted how physicians can sequence these agents appropriately in their patients.
Read More
Immunotherapy Options Growing for Metastatic Colorectal Cancer
October 14th 2019Immunotherapeutic agents have grown in popularity for treating mismatch repair–deficient metastatic colorectal cancer, becoming the standard of care in the second line, Howard Hochster, MD, told an audience at the 2019 Gastrointestinal Oncology Conference. Furthermore, ongoing clinical trials suggest that these agents may play a larger role in treating CRC going forward.
Read More
Choosing Between Systemic Therapy and TACE for HCC
October 11th 2019What is the ideal first-line therapy for nonresectable, non–transplantable eligible, liver-only hepatocellular carcinoma? In a debate at the 2019 Gastrointestinal Oncology Conference, Mark Yarchoan, MD, had the unenviable task of convincing the audience that systemic therapy was the way to go.
Read More
Neoadjuvant Chemotherapy Prior to Surgery Holds Benefit in Pancreatic Cancer
October 11th 2019In an interview with <em>Targeted Oncology</em>, Michael A. Choti, MD, MBA discussed the treatment landscape for patients with pancreatic cancer, as well as how the role of neoadjuvant chemotherapy in this space is changing. He highlights advantages of neoadjuvant strategies, and also some other treatment options for patients with pancreatic cancer.
Read More
Seeking Answers for Pancreatic Treatment Beyond FOLFIRINOX
October 10th 2019The FOLFIRINOX regimen remains the treatment of choice for patients with pancreatic cancer even as clinical trials exploring potential therapies, including CD40 and CPI-613, offer the possibility of new options for a notoriously difficult-to-treat disease, Davendra P.S. Sohal, MD, MPH, told an audience at the 2019 Gastrointestinal Oncology Conference.
Read More